Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine

被引:11
作者
Uehara, Shotaro [1 ,2 ]
Murayama, Norie [2 ]
Nakanishi, Yasuharu [1 ]
Nakamura, Chika [1 ]
Hashizume, Takanori [3 ]
Zeldin, Darryl C. [4 ]
Yamazaki, Hiroshi [2 ]
Uno, Yasuhiro [1 ]
机构
[1] Shin Nippon Biomed Labs Ltd, Pharmacokinet & Bioanal Ctr, Wakayama, Japan
[2] Showa Pharmaceut Univ, Lab Drug Metab & Pharmacokinet, Machida, Tokyo 1948543, Japan
[3] Osaka Ohtani Univ, Fac Pharm, Tondabayashi, Osaka, Japan
[4] NIEHS, Div Intramural Res, Durham, NC USA
关键词
Cynomolgus monkey; cytochrome P450; expression; liver; small intestine; CYTOCHROME-P450; ENZYMES; DRUG-METABOLISM; MICROSOMES; GENE; EBASTINE; JAPANESE; POLYMORPHISM; INVOLVEMENT; EXPRESSION; VARIANTS;
D O I
10.3109/00498254.2014.952800
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. An increasing number of studies have indicated the roles of CYP4 proteins in drug metabolism; however, CYP4 expression has not been measured in cynomolgus monkeys, an important animal species for drug metabolism studies. 2. In this study, cynomolgus CYP4A11, CYP4F2/3, CYP4F11 and CYP4F12, along with CYP2J2, were immunoquantified using selective antibodies in 28 livers and 35 small intestines, and their content was compared with CYP1A, CYP2A, CYP2B6, CYP2C9/19, CYP2D, CYP2E1, CYP3A4 and CYP3A5, previously quantified. 3. In livers, CYP2J2, CYP4A11, CYP4F2/3, CYP4F11 and CYP4F12, varied 1.3- to 4.3-fold, represented 11.2, 14.4, 8.0, 2.7 and 0.3% of total immunoquantified CYP1-4 proteins, respectively. 4. In small intestines, CYP2J2, CYP4F2/3, CYP4F11 and CYP4F12, varied 2.4- to 9.7-fold, represented 6.9, 36.4, 2.4 and 9.3% of total immunoquantified CYP1-4 proteins, respectively, making CYP4F the most abundant P450 subfamily in small intestines. CYP4A11 was under the detection limit in all of the samples analyzed. 5. Significant correlations were found in liver for CYP4A11 with lauric acid 11-/12-hydroxylation and for CYP4F2/3 and CYP4F11 with astemizole hydroxylation. 6. This study revealed the relatively abundant contents of cynomolgus CYP2J2, CYP4A11 and CYP4Fs in liver and/or small intestine, suggesting their potential roles for the metabolism of xenobitotics and endogenous substrates.
引用
收藏
页码:124 / 130
页数:7
相关论文
共 31 条
  • [1] Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis
    Danese, E.
    Montagnana, M.
    Johnson, J. A.
    Rettie, A. E.
    Zambon, C. F.
    Lubitz, S. A.
    Suarez-Kurtz, G.
    Cavallari, L. H.
    Zhao, L.
    Huang, M.
    Nakamura, Y.
    Mushiroda, T.
    Kringen, M. K.
    Borgiani, P.
    Ciccacci, C.
    Au, N. T.
    Langaee, T.
    Siguret, V.
    Loriot, M. A.
    Sagreiya, H.
    Altman, R. B.
    Shahin, M. H. A.
    Scott, S. A.
    Khalifa, S. I.
    Chowbay, B.
    Suriapranata, I. M.
    Teichert, M.
    Stricker, B. H.
    Taljaard, M.
    Botton, M. R.
    Zhang, J. E.
    Pirmohamed, M.
    Zhang, X.
    Carlquist, J. F.
    Horne, B. D.
    Lee, M. T. M.
    Pengo, V.
    Guidi, G. C.
    Minuz, P.
    Fava, C.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (06) : 746 - 756
  • [2] Cytochrome P450-Dependent Catabolism of Vitamin K: ω-Hydroxylation Catalyzed by Human CYP4F2 and CYP4F11
    Edson, Katheryne Z.
    Prasad, Bhagwat
    Unadkat, Jashvant D.
    Suhara, Yoshitomo
    Okano, Toshio
    Guengerich, F. Peter
    Rettie, Allan E.
    [J]. BIOCHEMISTRY, 2013, 52 (46) : 8276 - 8285
  • [3] Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal Microsomes
    Hashizume, T
    Imaoka, S
    Mise, M
    Terauchi, Y
    Fujii, T
    Miyazaki, H
    Kamataki, T
    Funae, Y
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (01) : 298 - 304
  • [4] Hashizume T, 2001, DRUG METAB DISPOS, V29, P798
  • [5] Human cytochrome P450 family 4 enzymes:: Function, genetic variation and regulation
    Hsu, Mei-Hui
    Savas, Uezen
    Griffin, Keith J.
    Johnson, Eric F.
    [J]. DRUG METABOLISM REVIEWS, 2007, 39 (2-3) : 515 - 538
  • [6] CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis
    Jin, Yi
    Zollinger, Markus
    Borell, Hubert
    Zimmerlin, Alfred
    Patten, Christopher J.
    [J]. DRUG METABOLISM AND DISPOSITION, 2011, 39 (02) : 191 - 198
  • [7] Cytochrome P4504F subfamily: At the crossroads of eicosanoid and drug metabolism
    Kalsotra, Auinash
    Strobel, Henry W.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2006, 112 (03) : 589 - 611
  • [8] Cloning of CYP2J2 gene and identification of functional polymorphisms
    King, LM
    Ma, JX
    Srettabunjong, S
    Graves, J
    Bradbury, JA
    Li, LP
    Spiecker, M
    Liao, JK
    Mohrenweiser, H
    Zeldin, DC
    [J]. MOLECULAR PHARMACOLOGY, 2002, 61 (04) : 840 - 852
  • [9] Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome p450 enzymes: Major roles for CYP2J2 and CYP3A
    Liu, Kwang-Hyeon
    Kim, Mi-Gyung
    Lee, Dong-Jun
    Yoon, Yune-Jung
    Kim, Min-Jung
    Shon, Ji-Hong
    Choi, Chang Soo
    Choi, Young Kil
    Desta, Zeuresenay
    Shin, Jae-Gook
    [J]. DRUG METABOLISM AND DISPOSITION, 2006, 34 (11) : 1793 - 1797
  • [10] Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole
    Matsumoto, S
    Hirama, T
    Matsubara, T
    Nagata, K
    Yamazoe, Y
    [J]. DRUG METABOLISM AND DISPOSITION, 2002, 30 (11) : 1240 - 1245